Alzamend Neuro, Inc. (ALZN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.84

From 52W high−27.59%

Volume240533.00

Market cap$9.12M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.84

From 52W high

−27.59%

Volume

240533.00

Market cap

$9.12M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

74.7

MomentumView details →

1D Return

+2.72%

YTD Return

+1.65%

SummaryUpdated Jul 1, 2026

Alzamend Neuro, Inc. (NASDAQ:ALZN) is an early-stage biopharmaceutical company founded in 2016 and headquartered in Atlanta, Georgia. The company went public in June 2021 and focuses on developing therapeutic treatments for neurodegenerative diseases and psychiatric disorders, with particular emphasis on Alzheimer's disease. As a clinical-stage biotech firm, Alzamend operates in the highly regulated pharmaceutical development space, where companies typically spend years and significant capital conducting clinical trials before potentially bringing products to market.

Ask drillr about Alzamend Neuro, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−156.77%

ROA (TTM)

−106.49%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+74.50%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+76.77%

EBITDA YoY

−47.39%

MomentumView details →

1D Return

+2.72%

YTD Return

+1.65%

1Y Return

−22.92%

RSI (14)

74.7

vs 50D SMA

+23.63%

vs 200D SMA

+16.95%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.01x

Quick Ratio

3.01x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.68

EPS Surprise

−21.43%

Beats (12Q)

6/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

24.58%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−9.10M

Op. CF (TTM)

−6.84M

Next earningsDec 8, 2026 →

Latest newsMore news →

Alzamend Neuro announced the initial closing of a securities purchase agreement with Ault Lending, receiving $7.5 million in gross proceeds from the sale of Series D Convertible Preferred Stock, with up to $17.5 million in additional funding available through subsequent tranches.47d ago

Similar companies

Ensysce Biosciences, Inc.ENSC ZyVersa Therapeutics, Inc.ZVSA Aprea Therapeutics, Inc.APRE COSCIENS Biopharma Inc.CSCI CollPlant Biotechnologies Ltd.CLGN FibroBiologics, Inc. Common StockFBLG Find similar companies →

Latest newsMore news →